Qingdao Pusheng Puli Enterprise Management Center (Limited Partnership) agreed to acquire 42.1204% stake in Guangzhou Gloria Biosciences Co., Ltd. from HARBIN GLORIA PHARMACEUTICALS Co., LTD (SZSE:002437) for CNY240 million on June 28, 2023. This has been approved by the HARBIN GLORIA PHARMACEUTICALS Co., LTD (SZSE:002437) 6th directorate during its 5th meeting held on June 28, 2023 and this is subject to approval by the HARBIN GLORIA PHARMACEUTICALS Co., LTD (SZSE:002437) shareholders’ meeting. Financials for the year ended December 31, 2023 Total assets for CNY460 million, Net assets of CNY330 million, Operating revenue of CNY120 million, Operating Loss of CNY590 million and Net Loss of CNY590 million.